

Advanced Enzyme Technologies Ltd. CIN: L24200MH1989PLC051018 Sun Magnetica, 'A' wing, 5th Floor, LIC Service Road, Louiswadi, Thane (W)-400 604, India Tel: +91-22-4170 3200, Fax: +91-22-2583 5159 Email: info@advancedenzymes.com, www.advancedenzymes.com

February 07, 2022

BSE Limited P. J. Towers, Dalal Street, Mumbai- 400 001 National Stock Exchange of India Limited Exchange Plaza, Plot No. C/1, G Block Bandra-Kurla Complex, Bandra (E) Mumbai- 400 051

Scrip Code-540025

Trading Symbol-ADVENZYMES

Dear Sir,

Sub: Newspaper publication of Extract of Un-audited Consolidated Financial Results for the quarter and nine months ended December 31, 2021. Ref: ISIN: INE837H01020

Pursuant to the provisions of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed copy of the newspaper publication of 'Extract of Un-audited Consolidated Financial Results for the quarter and nine months ended December 31, 2021' published in The Free Press Journal and Navshakti on February 06, 2021.

Thanking you, Yours faithfully, **For Advanced Enzyme Technologies Limited**

Sanjay Basantani Company Secretary and Head – Legal

Encl.: As above

WELCOME TO THE WORLD OF BETTER BUSINESS

THE FREE PRESS JOURNAL www.freepressjournal.in MUMBAI | SUNDAY | FEBRUARY 6, 2022

Regd. Office and Corpor Louiswadi, Thane - 400604, Mahar	I No.: L2420 ate Office: S ashtra, India	OMH1989P Sun Magnet . Tel No : 9	LC051018 ica, 5th Flo 1-22-41703	or, LIC Ser	vice Road, o: +91-22-2	
Website: www.advancede	and the state of the state of the	a series and a series of the			·	ABORA"
EXTRACT OF UNAUDITED CONSOLIDATED FINANC	IAL RESULTS FO	OR QUARTER	AND NINE N	IONTHS END	ED DECEMBE	R 31, 2021
New York Contract of the			(₹in mili	ion except	the Earnings	s per share
A description of the second	Quarter Ended Dec 31, 2021 Sep 30, 2021 Dec 31, 2020			Nine Mon	Year Ended	
Particulars	in the second	dual day			Dec 31, 2020 (Unaudited)	Audited (Revised)
Total income from operations	1,335.58	1,270.77	(Unaudited)	3.976.49	3.686.25	(Refer note iii) 5,018.41
Net Profit / (Loss) for the period (before tax,	1,000,00	1,270.77	/1,3/1.30	3,910.49	3,000.23	0,010.41
exceptional and/ or extraordinary items)	411.23	412.44	609.07	1,371.10	1,626.00	2,101.31
Net Profit / (Loss) for the period before tax (after exceptional and/ or extraordinary items)	411.23	412.44	609.07	1,371.10	1.626.00	2,101.31
Net Profit / (Loss) for the period after tax	11					
(after Exceptional and/or Extraordinary items) Total Comprehensive Income for the period	285.55	302.70	443.03	985.44	1,176.67	1,512.86
[Comprising Profit / (Loss) for the period (after tax) and Other Comprehensive Income (after tax)]	280.70	281.42	413.44	1,031.89	1,066.89	1,413.56
Equity Share Capital	223.58	223.56	223.45	223.58	223.45	223.46
Reserves excluding Revaluation Reserve as per the last audited Balance Sheet	1 10.21	ALC: A	- Kei	LAND O	115151	9,485.92
		and the second s	ALCONOMIC ADDRESS OF	12002 10 5 20	C BALER PROPERTY	
Earnings Per Share of ₹ 2 each (not annualised) (for continuing and discontinued operations) Basic	2.46	2.66	3.86	8.51	10.25	13.07
(for continuing and discontinued operations) Basic Diluted Notes: I) The above is an extract of the detailed format of consolid or the "Holding Company") and the financial results of	he subsidiary co	ompanies, Adv	anced Bio-Agr	o Tech Limited	(India), Advar	nced Enzytech
(for continuing and discontinued operations) Basic Diluted Notes: () The above is an extract of the detailed format of consolid or the "Holding Company") and the financial results of Solutions Limited (India), JC Biotech Private Limited Enzymes USA, Inc. (U.S.A.), Cal India Foods Interna Innovation, Inc. (U.S.A.), Dynamic Enzymes, Inc. (U.S.J (Netherlands) and Evoxx Technologies GmbH (Germa ii) The above is an extract of the detailed format of consc 2021 filed with the Stock Exchange under Regulation full format of quarterly results (standalone and conso Stock Exchange's website: www.bseindia.com and ww (ISSPL) for a total consideration of Rs 316.26 million. A finalised the purchase price allocation for the acquisiti amounts of goodwill of Rs. 13.54 million. The Group on Rs. 320.00 million resulting in Capital reserve of Rs September 2021 and quarter ended 31 December 202 2021 to 30 September 2021 and 1 October 2021 to 310 e 211.25 million. Post this additional acquisition the Con 15% by the Company in JC Biotech Private Limited No million in other equity. V) The above financial results of the Company were revio	2.45 ated unaudited fit he subsidiary cc (India), Scitech- tional (U.S.A.), (India), Scitech- tional (U.S.A.), (India), Scitech- tional (U.S.A.), (India), Scitech- lidated unaudite (India), Indiana (India), India), India), India), Indiana (India), India), India), India), India), Indiana (India), India), India), Indiana (India), India), Indi	2.65 mancial results of mpanies, Adv Specialities Pr Advanced Sup zymes (Malayz Company and d financial res Isting Obligation uarter and nin and on Compa the paid up er 21, the Group rended on 30 rended on 30 rend	3.85 of Advanced Er anced Bio-Agrivate Limited (pplementary Te sia) Sdn. Bhd. (its subsidiary to its subsidiary to an and Disclos en months end iny's website : quilty share can has accounted September 20 cettion has red s for the year SPL from the p ot comparable soldiary JC Bio ubsidiary JC Bio ubsidiary JC Bio	8.50 nzyme Technol o Tech Limited India) (w.e.f. cchnologies Cr Malaysia), Adh companies cor arter and nine ure Requirem ww.advancee pital in SciTech for the acquis 21 and accord ognised fair va ended 31 Ma eriod 11 Jan 2 ended 31 Ma eriod 11 Jan 2 account of acq , 123.67 millio	10.24 ogies Limited (I (India), Advar 11 January 20; orporation (U. 3) orporation (U. 3) orporation (U. 3) orporation (U. 3) months ended ents) Regulatic over 2021 are a benzymes.com n Specialties F ition on provisis ingly, revised 1 blue of Net Assi rch 2021, qua 021 to 31 Marc us correspond mitled for cons usistion of addi n and and adju	13.04 the "Company inced Enzytec 21), Advances S.A.), Enzyme se Europe B.V. oug". 31 Decembe ons, 2015. The vailable on th 1. Private Limitec onal basis and the provisional sis acquired of the provisional the pr
(for continuing and discontinued operations) Basic Diluted Votes: 1) The above is an extract of the detailed format of consolid or the "Holding Company") and the financial results of Solutions Limited (India), JC Biotech Private Limited Enzymes USA, Inc. (U.S.A.), Cal India Foods Interna Innovation, Inc. (U.S.A.), Cynamic Enzymes, Inc. (U.S.J (Netherlands) and Evoxx Technologies GmbH (Germa ii) The above is an extract of the detailed format of conso 2021 filed with the Stock Exchange under Regulation full format of quarterly results (standalone and conso Stock Exchange's website: www.bseindia.com and ww iii) On 11 January 2021, the Group completed the acquisiti amounts of goodwill of Rs. 13.54 million. The Group on Rs. 320.00 million resulting in Capital reserve of Rs September 2021 and quarter ended 31 December 202 2021 to 30 September 2021 and 1 October 2021 to 310 211.25 million. Post this additional acquisition the Con 15% by the Company in JC Biotech Private Limited No million in other equity. V) The above financial results of the Company were revis meeting held on S February 2022.	2.45 ated unaudited fit he subsidiary cc (India), Scitech tional (U.S.A.), .), Advanced En Indiated unaudite 13 of the SEBI (L (dated) for the q winseindia.com sition of 51% of s of 31 March 20 on in the quarter 3.74 million. A 1, which include cember 2021 res and ditional stake c upany holds 85% n-controlling inte	2.65 mancial results of mpanies, Adv Specialities Pr Advanced Sup zymes (Malaya Company and d financial res isting Obligation uarter and nin and on Compa the paid up et (21, the Group, ended on 30 hase price allo liso, the figure: s figures for S spectively, are r of 15% in its sul a stake in the s rest has been it Committee a	3.85 of Advanced Er anced Bio-Agr ivate Limited (plementary Te sia) Sdn. Bhd. (its subsidiary uits for the que on and Disclos e months end uits for the que on and Disclos e months end souths end souths accounted September 20 ocation has rec s for the year SPL from the p tot comparable solidiary JC Bio ubsidiary JC Bio ubsidiary JC Bio ubsidiary JC Bio	8.50 rzyme Technol o Tech Limitaci India) (w e.f. ' schnologies C Malaysia), Adi companies cor arter and nine- ure Requirem ed 31 Decemt www.advancec pital in ScTeci for the acquis 21 and accord ognised fair vz ended 31 Ma eriod 11 Jan 2 with the previce account of acq , 123.67 million approved by th	10.24 ogies Limited (I (India), Advar II January 20 orporation (U. vanced Enzyme months ended ents) Regulatic ver 2021 are a denzymes.com n Specialties F ition on provisi ingly, revised 1 m Specialties F ition on provisi ingly, revised 1 m Specialties F vancours and the vancours of add n and and adju the Board of Dir	13.04 the "Company icced Enzytec 21), Advances S.A.), Enzyme se Europe B.V oup". 31 Decembe ons, 2015. The vailable on th. 1. "rivate Limite onal basis and the provisiona ets acquired 0. ther ended 3. the 2021, 1 July ing periods. Ideration of R titonal stake of sted Rs. 87.54 rectors at their
(for continuing and discontinued operations) Basic Diluted Notes: I) The above is an extract of the detailed format of consolid or the "Holding Company") and the financial results of Solutions Limited (India), JC Biotech Private Limited Enzymes USA, Inc. (U.S.A.), Cal India Foods Interna Innovation, Inc. (U.S.A.), Cal India Foods Interna Innovation, Inc. (U.S.A.), Cal India Foods Interna ii) The above is an extract of the detailed format of conso 2021 filed with the Stock Exchange under Regulation 1 full format of quarterly results (standalone and conso Stock Exchange's website: www bseindia.com and ww iii) On 11 January 2021, the Group completed the acqui ("SSPL") for a total consideration of Rs 310.26 million, A finalised the purchase price allocation for the acquisiti amounts of goodwill of Rs. 13.54 million, The Group on Rs. 320.00 million resulting in Capital reserve of Rs September 2021 and quarter ended 31 December 2022 2021 to 30 September 2021 and 1 October 2021 to 31 De vi) Effective 18 August 2021, the Company has acquired a 211.25 million. Post this additonal acquisition the Con 15% by the Company in JC Biotech Private Limited No million in other equity. v) The above financial results of the Company were revi	2.45 ated unaudited fit he subsidiary cx (India), Scitech- tional (U.S.A.), Advanced Em V), The Holding lidated unaudite 3 of the SEBI (L (idated) for the q (idated) for the q s of 31 March 2C s of 31 March 2C awww.seindia.com sition of 51% of s of 31 March 2C awww.seindia.com sition of 51% of s of 31 March 2C comber 2021 res dditional stake of ppany holds 85% n-controlling inte awwed by the Aud	2.65 mancial results o mpanies, Adv Specialities Pr Advanced Sup zymes (Malayt Company and d financial res isting Obligation uarter and nin and on Compa the paid up eo 21, the Group ended on 30 thase price allo iso, the figures is figures for S3 spectively, arer of 15% in its sult is take in the s irrest has been lit Committee a Suparter Ende Sep 30, 2021	3.85 of Advanced Er anced Bio-Agrivate Limited (plementary Te sia) Sdn. Bhd., i is subsidiary ults for the qua on and Disclose en anothis endi- iny's website : quilty share can has accounted be accounted solution has rec so for the year SPL from the p boot comparable boldiary JC Bio ubsidiary JC Bio ubsidiary JC Bio ubsidiary JC Bio ubsidiary On a reduced by Rs and thereafter d	8.50 izyme Technol o Tech Limitec India) (w.e.f. ichnologies C Malaysia), Ad ichnologies, C Malaysia), Ad ichnologies, C ichnologies,	10.24 ogies Limited (I (India), Advar 11 January 20: orporation (U.3) vanced Enzyme stitute the "Gn months ended ents) Regulatic ber 2021 are a denzymes.com n Specialties F ition on provisi ingly, revised 1 alue of Net Assi rch 2021, qua 021 to 31 Marc us correspond imited for cons usition of addi n and and adju he Board of Dia ths Ended Dec 31, 2020	13.04 he "Company need Enzytect 21), Advances S.A.J, Enzym es Europe B.V. oug". 31 Decembe onal 2015. The vailable on the set on the provisione the provisio
(for continuing and discontinued operations) Basic Diluted Votes: 1) The above is an extract of the detailed format of consolid or the "Holding Company") and the financial results of Solutions Limited (India), JC Biotech Private Limited Enzymes USA, Inc. (U.S.A.), Cal India Foods Interna Innovation, Inc. (U.S.A.), Dynamic Enzymes, Inc. (U.S.J. (Netherlands) and Evoxx Technologies GmbH (Germa ii) The above is an extract of the detailed format of conso 2021 filed with the Stock Exchange under Regulation : tull format of quarterly results (standalone and conso Stock Exchange's website: www.bseindia.com and ww iii) On 11 January 2021, the Group completed the acqui (SSPL) for a total consideration of Rs 316.26 million. A finalised the purchase price allocation for the acquisiti amounts of goodwill of Rs. 13.54 million. The Group on Rs. 320.00 million resulting in Capital reserve of Rs September 2021 and quarter ended 31 December 202 2021 to 30 September 2021, the Company has acquired a 211.25 million. Post this additional acquisition the Con 15% by the Company in JC Biotech Private Limited No million in other equity. v) The above financial results of the Company were revis meeting held on S February 2022.	2.45 ated unaudited fit he subsidiary cc (India), Scitech tional (U.S.A.), (), Advanced En (India), Scitech tional (U.S.A.), (), Advanced En (Indiated unaudite i3 of the SEBI (L (dated) for the q (Indiated unaudite i3 of the SEBI (L (dated) for the q sition of 51% of s of 31 March 20 on in the quarter finalising of purc 3.74 million. A 1, which include comber 2021 res dditional stake of dditional stake of he-controlling inter awed by the Aud	2.65 mancial results are possible of the second specialities Pr Advanced Sup zymes (Malays Company and d financial res isting Obligatic uarter and nin and on Compa the paid up et 121, the Group ended on 30 ishase price allo iso, the figure is figures for S: spectively, are of f 15% in its sult is take in the s rest has been lit Committee a	3.85 of Advanced Er anced Bio-Agr viate Limited (plementary Te sia) Sdn. Bhd. its subsidiary its subsidiary uits for the qua on and Disclos e months endi- uits for the qua south of the subsidiary vity share can has accounted September 20 ocation has reco- solution the year SPL from the p loc comparable outbidiary. On i reduced by Rs and thereafter	8.50 nzyme Technol o Tech Limited India) (w e.f. ' schnologies C Malaysia), Ad companies cor arter and nine- ure Requirem ed 31 Decemt www.advancee pital in SCTeci for the acquis 21 and accord ognised fair va ended 31 Ma eriod 11 Jan 2 with the previo tech Private L account of acq. 123.67 millio approved by the Nine Mon	10.24 ogies Limited (I (India), Advar 11 January 200 orporation (U.3 vanced Enzymes months ended ents) Regulatic ver 2021 are a denzymes.com a Specialties F ition on provisi ingly, revised 1 alue of Net Assa rch 2021, qua 021 to 31 Marc us correspond imited for cons usisition of add n and and adju he Board of Dir ths Ended	13.04 the "Company iccel Enzytec; 1), Advances S.A.), Enzyme as Europe B.V oup". 31 Decembe ons, 2015. The vailable on th 1. vailable on th 1. "Trivate Limiter onal basis and the provisiona ets acquired on the rended 31 thomas take on the rended 31 thomas take on thomas and thomas an
(for continuing and discontinued operations) Basic Diluted Notes: 1) The above is an extract of the detailed format of consolid or the "Holding Company") and the financial results of Solutions Limited (India), JC Biotech Private Limited Enzymes USA, Inc. (U.S.A.), Cal India Foods Interna Innovation, Inc. (U.S.A.), Cal India Foods Interna Innovation, Inc. (U.S.A.), Dynamic Enzymes, Inc. (U.S.J. (Netherlands) and Evoxx Technologies GmbH (Germa 10) The above is an extract of the detailed format of conso 2021 filed with the Stock Exchange under Regulation : full format of quarterly results (standalone and conso Stock Exchange's website: www.bseindia.com and ww 10) On 11 January 2021, the Group completed the acqui ('SSPL') for a total consideration of Rs 316.26 million.A finalised the purchase price allocation for the acquisiti amounts of goodwill of Rs. 13.54 million. The Group on Rs. 320.00 million resulting in Capital reserve of Rs September 2021 and quarter ended 31 December 202 2021 to 30 September 2021 and 1 October 2021 to 31 Dec 211.25 million. Post this additonal acquisition the Com 15% by the Company in JC Biotech Private Limited No million in other equity. v) The above financial results of the Company were revisa meeting held on 5 February 2022. vi) The key standalone financial information are as under: Particulars	2.45 ated unaudited fit he subsidiary cx (India), Scitech tional (U.S.A.), Advanced Em V), The Holding lidated unaudite 3 of the SEBI (L (idated) for the qui (idated) for the qui ated) for the qui so fa 11 March 20 so fa 11 March 20 aver a state of the solution of 51% of so fa 11 March 20 comber 2021 res dditional state of ppany holds 85% n-controlling inte aver by the Audited	2.65 mancial results of mpanies, Adv Specialities Pr Advanced Sup zymes (Malayz Company and d financial res isting Obligation uarter and nin and on Compa the paid up eo 21, the Group ended on 30 thase price allo iso, the figures is figures for Si spectively, are r of 15% in its sul is take in the s rest has been lit Committee a Sep 30, 2021 Unaudited	3.85 of Advanced Er anced Bio-Agr ivate Limited (plementary Te sia) Sdn. Bhd., its subsidiary ults for the qua- on and Disclos en and Disclos en and the sed in y's website : quity share can has accounted by the sed sequence of the year SPL from the p occation has rec s for the year SPL from the p occation has rec soldiary JC Bio ubsidiary JC B	8.50 izyme Technol o Tech Limitec India) (w.e.f. ichnologies C. Malaysia), Adi companies con arter and nine ure Requireme www.advancer bital in SciTech for the acquis www.advancer bital in SciTech Ifor the acquis 21 and accord ognised fair va ended 31 Ma eriod 11 Jan 2 21 and accord ognised fair va ended 31 Ma eriod 11 Jan 2 itach Private L account of acq , 123.67 million approved by ti Nine Mon Dec 31, 2021 Unaudited	10.24 ogies Limited (I (India), Advar 11 January 20: orporation (U.3 vanced Enzyms stitute the "Gn months ended ents) Regulatic ber 2021 are a denzymes.com n Specialties F tition on provisis ingly, revised 1 blue of NetAssi rch 2021, qua 021 to 31 Marc us correspond imited for cons usistion of addi n and and adju the Board of Dii ths Ended Dec 31, 2020 Unaudited	13.04 he "Company inced Enzytecl 21), Advances S.A.), Enzym es Europe B.V. oup". 31 Decembe ons, 2015. Thi vailable on thi Private Limitec onal basis and the provisions. Private Limitec acquired on the provisions. deration of R. titonal stake of sted Rs. 87.53 rectors at their Mar 31, 2021 Audited

/

11

CIN Regd. Office and Corpora Louiswadi, Thane - 400604, Mahara Website: www.advanceder	shtra, India. Izymes.com	0MH1989P Sun Magnet Tel No : 9 , Email Id :	LC051018 ica, 5th Flo 1-22-41703 sanjay@a	or, LIC Ser 220 Fax N dvanceden:	vice Road, o: +91-22-2 zymes.com	25835159		
EXTRACT OF UNAUDITED CONSOLIDATED FINANCI	AL RESULTS FO	OR QUARTER		and the second	COMPOSED IN COMPOSED			
Particulars	(₹ in million except the Earnings per share) Quarter Ended Nine Months Ended Year Ended							
	Dec 31, 2021	Sep 30, 2021	Dec 31, 2020	Dec 31, 2021	Dec 31, 2020	Mar 31, 2021 Audited (Revised)		
Total income from operations	(Unaudited) 1,335.58	(Unaudred) 1,270.77	(Unaudited) 1,377.38	(Unaudited) 3,976.49		(Refer note III)		
Net Profit / (Loss) for the period (before tax,	1,000.00	1,270.77	1,011.00	3,970.49	3,686.25	5,018,41		
exceptional and/ or extraordinary items)	411.23	412.44	609.07	1,371.10	1,626.00	2,101.31		
Net Profit / (Loss) for the period before tax (after exceptional and/ or extraordinary items)	411.23	412.44	609.07	1,371.10	1,626.00	2,101.31		
Net Profit / (Loss) for the period after tax (after Exceptional and/or Extraordinary items)	285.55	302.70	443.03	985.44	1,176.67	1,512.86		
Total Comprehensive Income for the period [Comprising Profit / (Loss) for the period (after tax)	1	002.70		500.44	the state	1,012.00		
and Other Comprehensive Income (after tax)]	280.70	281.42	413.44	1,031.89	1,066.89	1,413.56		
Equity Share Capital Reserves excluding Revaluation Reserve	223.58	223.56	223.45	223.58	223.45	223.46		
as per the last audited Balance Sheet			1			9,485.92		
Earnings Per Share of ₹ 2 each (not annualised) (for continuing and discontinued operations)	0.40	0.00	0.00	0.54	40.05	(0.07		
Basic Diluted	2.46	2.66	3.86	8,51 8,50	10.25	13.07 13.04		
				India) (wet		 Advanced 		
Solutions Limited (India), JC Biotech Private Limited (I Enzymes USA, Inc. (U.S.A.), Cal India Foods Internati Innovation, Inc. (U.S.A.), Dynamic Enzymes, Inc. (U.S.A. (Netherlands) and Evox Technologies GmbH (German II) The above Is an extract of the detailed format of consoli 2021 filed with the Stock Exchange under Regulation 33 full format of quarterly results (standalone and consolin Stock Exchange's website: www.bseindia.com and www III) On 11 January 2021, the Group completed the acquis Stock Exchange's website: www.bseindia.com and www III) On 11 January 2021, the Group completed the acquisitio amounts of good/will of Rs. 13.54 million. The Group onf Rs. 320.00 million resulting in Capital reserve of Rs. September 2021 and quarter ended 31 December 2021 2021 to 30 September 2021 and 10 otober 2021 to 31 Dec VI) Effective 18 August 2021, the Company has acquired at 211.25 million. Post this additional acquisition the Com 15% by the Company in JC Biotech Private Limited Non million in other equity. v) The above financial results of the Company were revier meeting held on 5 February 2022.	onal (U.S.A.), / Advanced Em y). The Holding dated unaudite 8 of the SEBI (L fated) for the q unseindia.com ition of 51% of of 31 March 20 n in the quarter of	Advanced Sup zymes (Malay) Company and d financial res isting Obligati uarter and nin and on Compe the paid up ex 21, the Group ended on 30 hase price allo so, the figure s figures for S spectively, are r f 15% in its sul s take in the s rest has been	pplementary Te sia) Sdn. Bhd. (Ifs subsidiary ults for the que on and Disclos en months end my's website: u quity share cap has accounted September 20 Sociation has rec s for the year SPL from the p ot comparable bsidiary JC Bio ubsidiary JC Bio ubsidiary On n reduced by Rs	chnologies C Malaysia), AM companies con arter and nine ure Requirem ad 31 Decemt www.advancet bital in SciTeci for the acquis 21 and accord ognised fair va ended 31 Ma eriod 11 Jan 2 eriod 11 Jan 2 account of acq .123.67 millio	orporation (U.3 ranced Enzymu stitute the "Gr months ended ants) Regulatic fenzymes.com n Specialties P litton on provisi lingly, revised 1 lule of Net Ass rch 2021, qua 021 to 31 Marc us correspond mited for cons uisition of add n and and adju	S.Å.), Enzyme es Europe B.V. oup ^o . 31 December vailable on the 1. Private Limited onal basis and the provisional ets acquired of rifer ended 30 ch 2021, 1 July ing periods. Ideration of Rs itional stake of sted Rs. 87.58		
Enzymes USA, Inc. (U.S.A.), Cal India Foods Internati Innovation, Inc. (U.S.A.), Dynamic Enzymes, Inc. (U.S.A.) (Netherlands) and Evox Technologies GmbH (German i) The above is an extract of the detailed format of consoli 2021 filed with the Stock Exchange under Regulation 33 full format of quarterly results (standalone and consoli Stock Exchange's website: www.bseindia.com and www ii) On 11 January 2021, the Group completed the acquis ('SSPL') for a total consideration of Rs 316.26 million. As finalised the purchase price allocation for the acquisitus amounts of goodwill of Rs. 13.54 million. The Group onf Rs. 320.00 million resulting in Capital reserve of Rs. September 2021 and quarter anded 31 December 2021 2021 to 30 September 2021 and 1 October 2021 to 31 Dec UFfective 18 August 2021, the Company has acquired at 211.25 million. Post this additional acquisition the Comp 15% by the Company in JC Blotech Private Limited Non million in other equity. v) The above financial results of the Company were revier meeting held on 5 February 2022.	onal (U.S.A.), / Advanced Em y). The Holding dated unaudite 8 of the SEBI (L fated) for the q unseindia.com ition of 51% of of 31 March 20 n in the quarter 3.74 million. Al , which include sember 2021 res of any holds 85% -controlling inte wed by the Aud	Advanced Sup zymes (Malay) Company and d financial res isting Obligati uarter and nin and on Compe the paid up ex 21, the Group ended on 30 hase price allo so, the figure s figures for S spectively, are r f 15% in its sul s take in the s rest has been	plementary Te sia) Sdn. Bhd. (Its subsidiary ults for the que on and Disclos e months endi- my's website: v juity share can has accounter September 20 ocation has reco- ocation has reco- ocation has reco- ocation has reco- bisidiary JC Bio bisidiary JC Bio bis	Analogies C Malaysia), Adv companies coi arter and nine ura Requirem ad 31 Decemt www.advanced bital in SCTeci for the acquis 21 and accord ognised fair va ended 31 Ma eriod 11 Jan 2 with the previc tech Private L account of acc .123.67 millio approved by the Nine Mon	broporation (U.: vanced Enzyme institute the "Gr months ended ants) Regulation fenzymes.com i Specialties F ition on provisi ingly, revised 1 ingly, revised 1 is Specialties F ition on provisi ingly, revised 1 ingly, revised 1	S.A.), Enzyme es Europe B.V. oup". 31 December ans, 2015. The valiable on the h. rrivate Limited onal basis and the provisional ets acquired of the revisional ets acquired of the revisional ets acquired of the revisional state of Rs. 87.58 rectors at their Year Ended		
Enzymes USA, Inc. (U.S.A.), Cal India Foods Internati Innovation, Inc. (U.S.A.), Dynamic Enzymes, Inc. (U.S.A.) (Netherlands) and Evox Technologies GmbH (German i) The above is an extract of the detailed format of consoll 2021 filed with the Stock Exchange under Regulation 33 full format of quarterly results (standalone and consolin Stock Exchange's website: www.bseindia.com and www ii) On 11 January 2021, the Group completed the acquisit Stock Exchange's website: www.bseindia.com and www iii) On 11 January 2021, the Group completed the acquisitio amounts of goodwill of Rs. 13.54 million. The Group on Rs. 320.00 million resulting in Capital reserve of Rs. September 2021 and quarter ended 31 December 2021 2021 to 30 September 2021 and 1 October 2021 to 31 Dec vi) Effective 18 August 2021, the Company has acquired at 211.25 million. Post this additional acquisition the Comp 15% by the Company in JC Blotech Private Limited Non million in other equity. v) The above financial results of the Company were revier meeting held on 5 February 2022. vi) The key standalone financial information are as under: Particulars Total income from operations	onal (U.S.A.), A Advanced Em 9), The Holding dated unaudite 3 of the SEBI (L fated) for the q unseindia.com ition of 51% of of 31 March 20 of	Advanced Sup zymes (Malays) Company and d financial res isting Obligati uarter and nin and on Compe the paid up ex 21, the Group ended on 30 hase price allo so, the figures of Sup ended on 30 hase price allo so, the figures of 5% in its sui- stake in the s rest has been it Committee a Sep 30, 2021 Unaudited 649.11	plementary Te sia) Sdn. Bhd. (Ifts subsidiary ults for the que on and Disclos e months end my's website : quity share cap has accounter. September 20 ocation has rec s for the year SPL from the p ot comparable bsidiary. On reduced by Rs and thereafter Dec 31, 2020 Unaudited 791.45	chnologies C Malaysia), AM companies coi arter and nine ure Requirem ed 31 Decemb ww.advancec- bital in SciTeci for the acquis 21 and accord ognised fair va ended 31 Ma eriod 11 Jan 2 account of acc .123.87 millio approved by th Nine Mon Dec 31, 2021 Unaudited 2,020.50	broporation (U.: ranced Enzyme months ended ants) Regulation fenzymes.com or Specialties F tition on provisi ingly, revised 1 bitle of Net Ass rch 2021, qua 021 to 31 Marc us correspond mited for consultion of add n and and adju ne Board of Di Dec 31, 2020 Unaudited 2,128.65	S.A.), Enzyme es Europe B.V. oup ^o . 31 December ns, 2015. The vallable on the 1. Private Limited onal basis and the provisional ets acquired of riter ended 30 th 2021, 1 July ing periods. Ideration of Rs titional stake of sted Rs. 87.58 rectors at their Year Ended Mar 31, 2021 Audited 2,834.73		
Enzymes USA, Inc. (U.S.A.), Cal India Foods Internati Innovation, Inc. (U.S.A.), Dynamic Enzymes, Inc. (U.S.A.) (Netherlands) and Evox Technologies GmbH (German 1) The above is an extract of the detailed format of consoll 2021 filed with the Stock Exchange under Regulation 33 full format of quarterly results (standalone and consolid Stock Exchange's website: www.bseindia.com and www ii) On 11 January 2021, the Group completed the acquisitio amounts of goodwill of Rs. 13.54 million. As finalised the purchase price allocation for the acquisitio amounts of goodwill of Rs. 13.54 million. The Group on Rs. 320.00 million resulting in Capital reserve of Rs. September 2021 and quarter ended 31 December 2021 2021 to 30 September 2021, the Company has acquired ac 211.25 million. Post this additional acquisition the Comp 15% by the Company in JC Biotech Private Limited Non million in other equity. •) The above financial results of the Company were revier meeting held on 5 February 2022. •i) The key standalone financial information are as under: Particulars	onal (U.S.A.), A Advanced Em V), The Holding dated unaudite 3 of the SEBI (L dated) for the q unseindia.com ition of 51% of of 31 March 20 ition of 51% of of 31 March 20 sember 2021 res diditional stake of aany holds 85% -controlling inte wed by the Aud	Advanced Sup zymes (Malay) Company and d financial res isting Obligati uarter and nin and on Compe the paid up ex 21, the Group ended on 30 hase price allo so, the figures of figures for S figures f	plementary Te sia) Sdn. Bhd. (Ifs subsidiary ults for the que on and Disclos e months end my's website: u quity share cap has accountee September 20 ocation has red September 20 ocation has red so for the year SPL from the p ot comparable bisidiary JC Bic ubsidiary JC Bic ubsi	chnologies C Malaysia), AM companies co arter and nine ure Requiremu ad 31 Decemt www.advancer bital in SciTeci for the acquis 21 and accord ognised fair va ended 31 Ma eriod 11 Jan 2 count of acc .123.67 millio approved by th Nine Mon Dec 31, 2021 Unaudited	broporation (U.: vanced Enzymu stitute the "Gr months ended ants) Regulatic fenzymes.com n Specialties F litten on provisi ingly, revised 1 lute of Net Ass rch 2021, qua 021 to 31 Marc us correspond mited for cons uisition of add n and and adju ne Board of Di ths Ended Dec 31, 2020 Unaudited	S.A.), Enzyme es Europe B.V. oup ^o . 31 December vailable on the h Private Limited onal basis and the provisional ets acquired of the rended 30 och 2021, 1 July ing periods. Ideration of Rs titional stake of sted Rs. 87.58 rectors at their Year Ended Mar 31, 2021 Audited		

मुंबई, रविवार, ६ फेब्रुवारी २०२२ | नव शक्ति ??